奥司他韦
神经氨酸酶
扎那米韦
化学
神经氨酸酶抑制剂
结合位点
唾液酸
突变
酶
病毒学
病毒
活动站点
甲型流感病毒
立体化学
生物化学
生物
基因
2019年冠状病毒病(COVID-19)
医学
传染病(医学专业)
病理
疾病
作者
Aaron J. Oakley,Susan Barrett,Thomas S. Peat,Janet Newman,Victor A. Streltsov,Lynne J. Waddington,Takehiko Saito,Masato Tashiro,Jennifer L. McKimm‐Breschkin
摘要
We have identified a virus, B/Perth/211/2001, with a spontaneous mutation, D197E in the neuraminidase (NA), which confers cross-resistance to all NA inhibitors. We analyzed enzyme properties of the D197 and E197 NAs and compared these to a D197N NA, known to arise after oseltamivir treatment. Zanamivir and peramivir bound slowly to the wild type NA, but binding of oseltamivir was more rapid. The D197E/N mutations resulted in faster binding of all three inhibitors. Analysis of the crystal structures of D197 and E197 NAs with and without inhibitors showed that the D197E mutation compromised the interaction of neighboring R150 with the N-acetyl group, common to the substrate sialic acid and all NA inhibitors. Although rotation of the E275 in the NA active site occurs upon binding peramivir in both the D197 and E197 NAs, this does not occur upon binding oseltamivir in the E197 NA. Lack of the E275 rotation would also account for the loss of slow binding and the partial resistance of influenza B wild type NAs to oseltamivir.
科研通智能强力驱动
Strongly Powered by AbleSci AI